PL2560662T3 - Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy - Google Patents

Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Info

Publication number
PL2560662T3
PL2560662T3 PL11723652T PL11723652T PL2560662T3 PL 2560662 T3 PL2560662 T3 PL 2560662T3 PL 11723652 T PL11723652 T PL 11723652T PL 11723652 T PL11723652 T PL 11723652T PL 2560662 T3 PL2560662 T3 PL 2560662T3
Authority
PL
Poland
Prior art keywords
sulodexide
metalloproteinases
pathologies
involved
treatment
Prior art date
Application number
PL11723652T
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Ferdinando Mannello
Cristiana Bruno
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2560662(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Publication of PL2560662T3 publication Critical patent/PL2560662T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11723652T 2010-04-23 2011-04-20 Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy PL2560662T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO2010A000250A IT1401253B1 (it) 2010-04-23 2010-04-23 Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Publications (1)

Publication Number Publication Date
PL2560662T3 true PL2560662T3 (pl) 2017-09-29

Family

ID=43063923

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11723652T PL2560662T3 (pl) 2010-04-23 2011-04-20 Sulodeksyd do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy
PL13161007T PL2609925T3 (pl) 2010-04-23 2011-04-20 Siarczan dermatanu do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13161007T PL2609925T3 (pl) 2010-04-23 2011-04-20 Siarczan dermatanu do zastosowania w leczeniu patologii, w których uczestniczą metaloproteinazy

Country Status (11)

Country Link
US (1) US8987231B2 (pl)
EP (2) EP2560662B1 (pl)
KR (2) KR20160060164A (pl)
CN (1) CN102883728A (pl)
ES (2) ES2628582T3 (pl)
IT (1) IT1401253B1 (pl)
MX (1) MX339537B (pl)
PL (2) PL2560662T3 (pl)
PT (2) PT2609925T (pl)
RU (1) RU2557996C2 (pl)
WO (1) WO2011132161A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP3060223B1 (en) * 2013-10-22 2017-08-30 Cell Receptor GmbH Sulfated polysaccharides for use in the treatment of cancer
CN104398533B (zh) * 2014-11-26 2017-03-08 山东辰中生物制药有限公司 舒洛地特的生产方法
RU2667650C1 (ru) * 2017-12-15 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения и профилактики острого тромбоза геморроидальных узлов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4705798A (en) 1985-09-27 1987-11-10 University Of Iowa Research Foundation Phenylephrine prodrug useful as mydriatic agent
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1242604B (it) * 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
HU219339B (en) 1993-09-30 2001-03-28 Seikagaku Kogyo Co Ltd Dermatan sulphate with low heparin or heparane sulphate content and pharmaceutical compositions comprising them
IT1274351B (it) 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
EA003294B1 (ru) 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
DE69833822D1 (de) 1998-10-01 2006-05-11 Giovanni Gambaro Substanzen zur Vorbeugung von krankhafter TGF-beta Überexpression und Methoden derer Ermittlung
US20040009952A1 (en) 1998-10-19 2004-01-15 Giovanni Gambaro TGF-beta gene overexpression preventing substances for the treatment of disorders connected with pathological overexpression of TGF-beta
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
ATE290874T1 (de) 2000-12-16 2005-04-15 Aventis Pharma Gmbh Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
FR2864087B1 (fr) 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
KR100808131B1 (ko) * 2006-06-22 2008-02-29 부경대학교 산학협력단 인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity

Also Published As

Publication number Publication date
WO2011132161A3 (en) 2012-03-08
RU2557996C2 (ru) 2015-07-27
PL2609925T3 (pl) 2019-02-28
PT2609925T (pt) 2018-11-22
RU2012142256A (ru) 2014-05-27
EP2609925A3 (en) 2013-09-04
PT2560662T (pt) 2017-07-10
WO2011132161A2 (en) 2011-10-27
MX2012012285A (es) 2012-11-23
US8987231B2 (en) 2015-03-24
MX339537B (es) 2016-05-30
KR20160060164A (ko) 2016-05-27
EP2560662B1 (en) 2017-06-07
KR101739757B1 (ko) 2017-05-25
ES2628582T3 (es) 2017-08-03
ES2694587T3 (es) 2018-12-21
EP2609925B1 (en) 2018-10-17
ITBO20100250A1 (it) 2011-10-24
EP2609925A2 (en) 2013-07-03
EP2560662A2 (en) 2013-02-27
IT1401253B1 (it) 2013-07-18
CN102883728A (zh) 2013-01-16
US20130045946A1 (en) 2013-02-21
KR20130072199A (ko) 2013-07-01

Similar Documents

Publication Publication Date Title
ES3060195T3 (en) Cytotoxicity-inducing therapeutic agent
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB2524689B (en) Cannabinoids for use in the treatment of neuropathic pain
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
PL2652193T3 (pl) Obróbka
IL275350B (en) Treatment of neoplastic diseases
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
PT2694107T (pt) Tratamento para patologias dermatológicas
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
IL225896A0 (en) Treatment of mecp-2 related disorders
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
IL232239A0 (en) Medical use
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PT2560662T (pt) Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas
GB201013573D0 (en) Treatment
GB201016486D0 (en) Compounds for the use in treatment of plants
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HK1181301A (en) Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
PL2456445T3 (pl) Środek do leczenia chorób skóry
GB201014097D0 (en) Treatment
GB201013068D0 (en) Liquid treatment
GB201105302D0 (en) Treatment of acidosis
GB201001659D0 (en) Body treatment product
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer